   | North Carolina. Good Call.
Sequenom looked at all U.S. life-science clusters for a unique diagnostics lab site. Only North Carolina had the complete business-friendly life-science package: a highly trained workforce from community college and university programs; low business costs; excellent access; seamless support. North Carolina. Good call. | - Experts ID birth defect gene in babies born to moms with diabetes
Researchers at the Joslin Diabetes Center in Boston found that maternal hyperglycemia in women with diabetes leads to oxidative stress in the embryo and inhibits the expression of a gene called Pax3 that is integral to the development of the neural tube. The AMP kinase enzyme prompts the cell nucleus to block the expression of Pax3 gene. The findings appear in Diabetologia. Yahoo!/Asian News International (10/17)       - MIT research could aid development of new HIV vaccines
MIT researchers have developed a new method for developing HIV vaccines. The technique can evaluate the response of T cells to HIV-infected cells, according to the study reported in the Journal of Clinical Investigation. The researchers said more studies need to be conducted before the technology can be used in vaccine studies. Mass High Tech (Boston) (10/17)  | Are you harnessing the power of standardization to boost your bottom line? Standards and conformance are powerful tools for reducing costs and expanding markets. C-suite executives at major U.S. companies are supporting standardization to save millions and gain a competitive advantage. Shouldn’t you? Visit www.standardsboostbusiness.org. |
 - Sequenom unveils blood test for Down syndrome
Sequenom has introduced its blood test for Down syndrome, called MaterniT21 LDT. The move follows a study published in the journal Genetics in Medicine that showed the test is 99.1% accurate. The test can detect and map unborn babies' DNA in maternal blood samples and determine whether they contain genetic codes that point to Down syndrome. San Diego Union-Tribune (10/17)  - Phyton Biotech gets life science award
San Antonio-based Phyton Biotech has received this year's Research Group of the Year 2011 Life Science Award. Phyton, a subsidiary of DFB Pharmaceuticals, has operated the world's biggest pharmaceutical cell fermentation plant near Hamburg, Germany, for more than 10 years and has the capacity to meet more than 60% of global demand for paclitaxel, an anti-cancer drug. "Phyton is very pleased to be the winner of this highly competitive award. Our research teams in both Germany and Canada have done great work together to develop an innovative, efficient and green process to produce important chemotherapeutic agents at a huge scale," said Phyton Chief Technical Officer Roland Franke. American City Business Journals/San Antonio (10/17)  | Enterprise Resource Planning automates many aspects of an organization's operations, cascading across traditional boundaries of operations, finance, manufacturing and more. As such, changes in the ERP market can cause a ripple effect in your business. Get ahead of the changing tide and trends by downloading this free whitepaper. |
| Industrial & Environmental |  |  | | - Coskata marks operational milestone at Penn. cellulosic-ethanol plant
Coskata this week passed a 15,000-run-hour milestone at its demonstration-scale cellulosic-ethanol plant in Madison, Penn. The facility uses wood biomass and municipal solid waste. "The data and operating experience cultivated at this pre-commercial scale facility has conclusively demonstrated that the Coskata technology is ready for commercial production today," said Coskata President and CEO Bill Roe. BiofuelsDigest.com (10/17) | News from BIO | | | | - Greater breadth of companies. Greater depth of knowledge
The 10th Annual BIO Investor Forum, to be held Oct. 25-26 in San Francisco, is a national investor forum exploring investment trends and opportunities in life sciences. Hear presentations from more than 110 late-stage private and emerging public companies you won't see at other investor conferences. Meet one-on-one with new and current investors, analysts and partnering companies. Gain insights from expert physicians, analysts and company scientific officers at candid therapeutic and business panels. For program registration and more information, visit the BIO Investor Forum website.
| Editor's Note | | | | - Correction
In yesterday's BIO SmartBrief, 3-prime oligonucleotides were incorrectly described in the summary "Experts ID new technique to diagnose cancer mutations." SmartBrief regrets the error. | SmartQuote | | | |  | Genius is nothing but a great aptitude for patience."
--Georges-Louis Leclerc, Comte de Buffon,
French naturalist, mathematician, cosmologist and author  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, October 17, 2011
- Friday, October 14, 2011
- Thursday, October 13, 2011
- Wednesday, October 12, 2011
- Tuesday, October 11, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment